EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access

Efficacy and safety of lacosamide in patients with trigeminal neuralgia: an 8-week pilot dose-escalation study

Pramot Lappichetpaiboon, Somsak Tiamkao, Supanigar Ruangsri, Jarin Paphangkorakit, Waranuch Pitiphat, Teekayu P Jorns

Journal of Oral & Facial Pain and Headache · 2025

DOI: 10.22514/jofph.2025.011 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Journal of Oral & Facial Pain and Headache, 2025. Verfasst von Pramot Lappichetpaiboon und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral Biomedical Science, Faculty of Dentistry, Khon Kaen University, 40002 Khon Kaen, Thailand. Hauptthemen laut MEDLINE: Anticonvulsants, Lacosamide, Trigeminal Neuralgia. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Khon Kaen University Neuroscience Research and Development Group (KKU-NRDG).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Trigeminal neuralgia (TN) is a severe neuropathic pain condition in the orofacial region, with carbamazepine recommended as the first-line treatment. Nonetheless, its application is constrained by unfavorable drug responses and side effects. The objective of this research was to assess the effectiveness and safety of lacosamide, a third-generation anticonvulsant, in individuals with TN, and to juxtapose the findings with observational records from recently diagnosed TN patients who underwent carbamazepine monotherapy within the corresponding timeframe.

Methods

An 8-week flexible dose titration of lacosamide was performed on newly diagnosed 12 TN patients who were divided into two groups: 200 mg/day (n = 5), and 400 mg/day (n = 7). Outcome measures included average pain score, Brief Pain Inventory-facial scores, and side effects. Patients were followed-up at 2, 4 and 8 weeks after baseline.

Results

The percentage change of pain score at 4-week visit was compared between both lacosamide groups and patients receiving carbamazepine (n = 6) for four weeks during concurrent period. Both lacosamide groups experienced a decrease in pain score at 2-week follow-up, and differences in average pain score reduction were not observed between the two groups across all visits (p > 0.05). The mean Brief Pain Inventory-facial score in the lacosamide 200 mg/day group was higher than that in the 400 mg/day group at the 2-week follow-up (p = 0.03). Interestingly, the 4-week follow-up revealed that there were no significant variances in pain intensity between the lacosamide and the contemporaneous carbamazepine cohorts (p > 0.05). Frequently noted adverse events were mild somnolence (n = 9), slight vertigo (n = 5), and emotional lability (n = 2) without instances of severe adverse drug responses.

Conclusions

Lacosamide demonstrates potential as a therapeutic option for patients suffering from trigeminal neuralgia. Clinical Trial Registration: TCTR20210811002.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsLacosamideTrigeminal NeuralgiaAdultAgedFemaleHumansMaleMiddle AgedAnalgesics, Non-NarcoticCarbamazepineDose-Response Relationship, DrugPain MeasurementPilot ProjectsTreatment Outcome

Stichwörter der Autor:innen

Brief pain inventory-facialCarbamazepineLacosamideTrigeminal neuralgia

Substanzen

Analgesics, Non-NarcoticAnticonvulsantsCarbamazepineLacosamide

Autor:innen und Institutionen

  • Department of Oral Biomedical Science, Faculty of Dentistry, Khon Kaen University, 40002 Khon Kaen, Thailand.
  • Department of Medicine, Faculty of Medicine, Khon Kaen University, 40002 Khon Kaen, Thailand.
  • Department of Preventive Dentistry, Faculty of Dentistry, Khon Kaen University, 40002 Khon Kaen, Thailand.

Förderung

  • Khon Kaen University Neuroscience Research and Development Group (KKU-NRDG)

Zitieren

APA

Lappichetpaiboon, P., Tiamkao, S., Ruangsri, S., Paphangkorakit, J., Pitiphat, W., & Jorns, T. P. (2025). Efficacy and safety of lacosamide in patients with trigeminal neuralgia: an 8-week pilot dose-escalation study. Journal of Oral & Facial Pain and Headache. https://doi.org/10.22514/jofph.2025.011

Vancouver

Lappichetpaiboon P, Tiamkao S, Ruangsri S, Paphangkorakit J, Pitiphat W, Jorns TP. Efficacy and safety of lacosamide in patients with trigeminal neuralgia: an 8-week pilot dose-escalation study. Journal of Oral & Facial Pain and Headache. 2025. doi:10.22514/jofph.2025.011

BibTeX
@article{Lappichetpaiboon2025,
  author = {Lappichetpaiboon, Pramot and Tiamkao, Somsak and Ruangsri, Supanigar and Paphangkorakit, Jarin and Pitiphat, Waranuch and Jorns, Teekayu P},
  title = {Efficacy and safety of lacosamide in patients with trigeminal neuralgia: an 8-week pilot dose-escalation study},
  journal = {Journal of Oral & Facial Pain and Headache},
  year = {2025},
  doi = {10.22514/jofph.2025.011}
}
Kostenlos starten →